Department of Laboratory Medicine, Karolinska Institutet, Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden.
Eur J Clin Pharmacol. 2010 Aug;66(8):791-5. doi: 10.1007/s00228-010-0820-7. Epub 2010 Apr 20.
The cytochrome P450 enzyme CYP2C9 metabolizes several important drugs, such as warfarin and oral antidiabetic drugs. The enzyme is polymorphic, and all known alleles, for example, CYP2C92 and3, give decreased activity. Ultra-high activity of the enzyme has not yet been reported.
We present a patient with Behçet's disease who required treatment with high doses of phenytoin. When fluconazole, a potent inhibitor of CYP2C9, was added to the treatment regimen, the patient developed ataxia, tremor, fatigue, slurred speech and somnolence, indicating phenytoin intoxication. On suspicion of ultra-high activity of CYP2C9, a phenotyping test for CYP2C9 with losartan was performed.
The patient was shown to have a higher activity of CYP2C9 than any of the 190 healthy Swedish Caucasians used as controls.
Our finding of an ultrarapid metabolism of losartan and phenytoin may apply to other CYP2C9 substrates, where inhibition of CYP2C9 may cause severe adverse drug reactions.
细胞色素 P450 酶 CYP2C9 代谢多种重要药物,如华法林和口服抗糖尿病药物。该酶呈多态性,所有已知的等位基因,如 CYP2C92 和3,均导致活性降低。尚未报道该酶具有超高活性。
我们报告了一例患有贝切特病的患者,需要用大剂量苯妥英钠治疗。当在治疗方案中加入氟康唑(一种强效 CYP2C9 抑制剂)时,患者出现共济失调、震颤、疲劳、言语不清和嗜睡,表明苯妥英钠中毒。由于怀疑 CYP2C9 具有超高活性,因此进行了洛沙坦 CYP2C9 表型检测。
与 190 名用作对照的瑞典白种人健康个体相比,该患者的 CYP2C9 活性更高。
我们发现洛沙坦和苯妥英钠的超快代谢可能适用于其他 CYP2C9 底物,其中 CYP2C9 的抑制可能导致严重的药物不良反应。